Most patients who died after withdrawal of life-sustaining therapy were considered to have recovery potential of at least 1 percent
THURSDAY, March 27, 2025 (HealthDay News) — Most comatose patients resuscitated from cardiac arrest who died after withdrawal of life-sustaining therapy (WLST) were considered by experts to have recovery potential of at least 1 percent, according to a study published online March 25 in JAMA Network Open.
Jonathan Elmer, M.D., from the University of Pittsburgh School of Medicine, and colleagues conducted a prospective cohort study including comatose adult patients treated following resuscitation from cardiac arrest at a single academic medical center between Jan. 1, 2010, and July 31, 2022. Three or more experts independently estimated recovery potential using a 7-point numerical ordinal scale for each patient if life-sustaining treatment had been continued.
A total of 2,391 patients were included; 714 (29.9 percent) survived to discharge. Thirty-eight experts reviewed cases of uncertain outcome (1,431 patients [59.8 percent]) in which WLST preceded death; they rendered 4,381 estimates of recovery potential. The researchers found that all experts believed that recovery potential was less than 1 percent if life-sustaining therapies had been continued in 518 cases (36.2 percent). At least one expert believed that recovery potential was at least 1 percent in the remaining 913 cases (63.8 percent). All experts agreed that recovery potential was at least 1 percent in 227 cases (15.9 percent); expert estimates differed at this threshold in 686 cases (47.9 percent).
“Our results suggest a potential for biased clinical decision-making and research when deaths after WLST are treated as poor outcomes that cannot be ignored,” the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Exercise Intervention Linked to Improved Attention, Memory in Breast Cancer
Cancer Survivors Have Lower Levels of Physical Activity
Childhood Cancer Survivors Often Have Mental Distress in Adulthood
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis